Healthcare / Medical DevicesOslo
$35.00
+0.50 (+1.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $11.0M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$541M
P/E
N/A
•EV/EBITDA
12.9x
↑ROE
6.5%
↑Gross Margin
55.6%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.2%
FCF CAGR
—
FCF margin
18.0%
FCF / Net income
2.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $176.5M · net income $13.3M · FCF $31.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $176.5M | $176.5M | $152.1M | $135.2M | $101.6M |
| Net Income | $13.3M | $13.3M | $45.3M | $-10.6M | $-23.6M |
| EBITDA | $35.5M | $35.5M | $29.7M | $-5000.00 | $-12.1M |
| EPS | — | — | 2.87 | -0.69 | -1.53 |
| Gross Margin | 55.6% | 55.6% | 54.5% | 47.5% | 48.2% |
| Operating Margin | 14.4% | 14.4% | 10.3% | -9.4% | -22.9% |
| Net Margin | 7.5% | 7.5% | 29.8% | -7.9% | -23.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.05 | 0.09 | 0.10 |
| Current Ratio | 5.70 | 5.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $31.8M | $31.8M | $2.5M | $11.0M | $-28.6M |
| Returns | |||||
| ROE | 6.5% | 6.5% | 23.3% | -7.3% | -15.3% |
| Valuation | |||||
| P/E | — | — | 13.94 | — | — |
| EV/EBITDA | 12.89 | 12.89 | 18.72 | — | — |
| P/B | 2.63 | 2.63 | 3.25 | 4.31 | 4.19 |
| Growth & Yield | |||||
| Revenue Growth | 16.1% | 16.1% | 12.5% | 33.0% | — |
| EPS Growth | — | — | 515.9% | 54.9% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.9%
Start / end P/E
n/dx → n/dx
EPS bridge
2.87 → n/d
Residual
-38.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.